AAAAAA

   
Results: 1-13 |
Results: 13
Can interleukin-2 reverse anthracyclin chemoresistance in metastatic soft tissue sarcoma patients. Results of a prospective phase II clinical trial
Authors: Gravis, G Mousseau, M Douillard, JY Dorval, T Fabbro, M Escudier, B Mignot, L Viens, P
Citation: G. Gravis et al., Can interleukin-2 reverse anthracyclin chemoresistance in metastatic soft tissue sarcoma patients. Results of a prospective phase II clinical trial, EUR CYTOKIN, 12(2), 2001, pp. 239-243
Response to chemotherapy is a major parameter-influencing long-term survival of metastatic breast cancer patients
Authors: Pierga, JY Robain, M Jouve, M Asselain, B Dieras, V Beuzeboc, P Palangie, T Dorval, T Extra, JM Scholl, S Pouillart, P
Citation: Jy. Pierga et al., Response to chemotherapy is a major parameter-influencing long-term survival of metastatic breast cancer patients, ANN ONCOL, 12(2), 2001, pp. 231-237
A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3
Authors: Coulie, PG Karanikas, V Colau, D Lurquin, C Landry, C Marchand, M Dorval, T Brichard, V Boon, T
Citation: Pg. Coulie et al., A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3, P NAS US, 98(18), 2001, pp. 10290-10295
Effect of adjuvant chemotherapy on outcome in patients with metastatic breast carcinoma treated with first-line doxorubicin-containing chemotherapy
Authors: Pierga, JY Asselain, B Jouve, M Dieras, V Carton, M Laurence, V Girre, V Beuzeboc, P Palangie, T Dorval, T Pouillart, P
Citation: Jy. Pierga et al., Effect of adjuvant chemotherapy on outcome in patients with metastatic breast carcinoma treated with first-line doxorubicin-containing chemotherapy, CANCER, 91(6), 2001, pp. 1079-1089
Cutaneous melanoma
Authors: Negrier, S Fervers, B Bailly, C Beckendorf, V Cupissol, D Dore, JF Dorval, T Garbay, JR Vilmer, C
Citation: S. Negrier et al., Cutaneous melanoma, BR J CANC, 84, 2001, pp. 81-85
Predictive factors of response to first-line chemotherapy in 1426 women with metastatic breast cancer
Authors: Robain, M Pierga, JY Jouve, M Asselain, B Dieras, V Beuzeboc, P Palangie, T Dorval, T Extra, JM Scholl, S Pouillart, P
Citation: M. Robain et al., Predictive factors of response to first-line chemotherapy in 1426 women with metastatic breast cancer, EUR J CANC, 36(18), 2000, pp. 2301-2312
Cytokines and soluble cytokine receptor induction after IL-12 administration in cancer patients
Authors: Haicheur, N Escudier, B Dorval, T Negrier, S De Mulder, PHM Dupuy, JM Novick, D Guillot, T Wolf, S Pouillart, P Fridman, WH Tartour, E
Citation: N. Haicheur et al., Cytokines and soluble cytokine receptor induction after IL-12 administration in cancer patients, CLIN EXP IM, 119(1), 2000, pp. 28-37
Standards, Options and Recommendations (SOR): clinical practice guidelinesfor diagnosis, treatment and follow-up of cutaneous melanoma
Authors: Negrier, S Fervers, B Bailly, C Beckendorf, V Cupissolv, D Dore, JF Dorval, T Garbay, JR Vilmer, C
Citation: S. Negrier et al., Standards, Options and Recommendations (SOR): clinical practice guidelinesfor diagnosis, treatment and follow-up of cutaneous melanoma, B CANCER, 87(2), 2000, pp. 173-182
Phase I clinical trial with IL-2-transfected xenogeneic cells administeredin subcutaneous metastatic tumours: clinical and immunological findings
Authors: Tartour, E Mehtali, M Sastre-Garau, X Joyeux, I Mathiot, C Pleau, J Squiban, P Rochlitz, C Courtney, M Jantscheff, P Herrmann, R Pouillart, P Fridman, WH Dorval, T
Citation: E. Tartour et al., Phase I clinical trial with IL-2-transfected xenogeneic cells administeredin subcutaneous metastatic tumours: clinical and immunological findings, BR J CANC, 83(11), 2000, pp. 1454-1461
Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer
Authors: Pierga, JY Mouret, E Dieras, V Laurence, V Beuzeboc, P Dorval, T Palangie, T Jouve, M Vincent-Salomon, A Scholl, S Extra, JM Asselain, B Pouillart, P
Citation: Jy. Pierga et al., Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer, BR J CANC, 83(11), 2000, pp. 1480-1487
Neoadjuvant chemotherapy in young breast cancer patients: Correlation between response and relapse?
Authors: Braud, AC Asselain, B Scholl, S De la Rochefordiere, A Palangie, T Dieras, V Pierga, JY Dorval, T Jouve, M Beuzeboc, P Pouillart, P
Citation: Ac. Braud et al., Neoadjuvant chemotherapy in young breast cancer patients: Correlation between response and relapse?, EUR J CANC, 35(3), 1999, pp. 392-397
Gene therapy study of cytokine-transfected xenogeneic cells (Vero-interleukin-2) in patients with metastatic solid tumors
Authors: Rochlitz, C Jantscheff, P Bongartz, G Dietrich, PY Quiquerez, AL Schatz, C Mehtali, M Courtney, M Tartour, E Dorval, T Fridman, WH Herrmann, R
Citation: C. Rochlitz et al., Gene therapy study of cytokine-transfected xenogeneic cells (Vero-interleukin-2) in patients with metastatic solid tumors, CANC GENE T, 6(3), 1999, pp. 271-281
Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma
Authors: Dorval, T Negrier, S Chevreau, C Avril, MF Baume, D Cupissol, D Oskam, R de Peuter, R Vinke, J Herrera, L Escudier, B
Citation: T. Dorval et al., Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma, CANCER, 85(5), 1999, pp. 1060-1066
Risultati: 1-13 |